Fig. 5
(A) Quantification of CHMP4B levels at midbody in HeLa cells treated with control siRNA or siRNA targeting PI3K-C2α, ALIX, or PI3K-C2α and ALIX. n ≥ 50 cells, mean ± SD. (B) Quantification of ALIX levels at midbody in HeLa cells transfected with ALIX-Cherry and treated with control or siRNA targeting PI3K-C2α or VPS36. n ≥ 60 cells, mean ± SD. (C) Quantification of CHMP4B levels at midbody in HeLa cells treated with control or siRNA targeting CHMP6. n ≥ 45 cells, mean ± SD. (D) Quantification of CHMP6 levels at midbody in HeLa cells transfected with GFP-CHMP6 and treated with control or siRNA targeting PI3K-C2α, VPS36, or ALIX. n ≥ 50 cells, mean ± SD. (E) Quantification of VPS36 levels at midbody in HeLa cells treated with control or siRNA targeting CHMP6. n ≥ 40 cells. If not previously specified, all results are shown as mean or representative picture of at least three independent experiments. (n.s. = not significant; **P < 0.01; ***P < 0.001).